Axsome Therapeutics (NASDAQ:AXSM) Given New $212.00 Price Target at Mizuho

Axsome Therapeutics (NASDAQ:AXSM) had its price target upped by Mizuho from $195.00 to $212.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts have also recently issued reports on AXSM. Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. HC Wainwright boosted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Bank of America raised their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Finally, Wells Fargo & Company increased their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $160.00.

Axsome Therapeutics Trading Up 1.0 %

AXSM opened at $128.33 on Wednesday. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The stock has a market capitalization of $6.26 billion, a PE ratio of -21.42 and a beta of 1.05. The firm’s fifty day moving average price is $102.78 and its 200 day moving average price is $95.62.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, research analysts expect that Axsome Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AXSM. Raiffeisen Bank International AG acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at $51,000. Assetmark Inc. bought a new position in Axsome Therapeutics in the 4th quarter valued at about $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the 4th quarter valued at about $64,000. Aquatic Capital Management LLC bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth about $76,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $86,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.